Which has preferable earnings and valuation, MESO or SYRE?

Mesoblast has higher revenue and earnings than Spyre Therapeutics. Mesoblast is trading at a lower price-to-earnings ratio than Spyre Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mesoblast $120.25M 15.16 -$57.50M -$0.28 N/A Spyre Therapeutics $890K 9,103.57 -$155.20M -$1.95 N/A

Is MESO or SYRE more profitable?

Mesoblast's return on equity of 0.00% beat Spyre Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Mesoblast N/A N/A N/A Spyre Therapeutics N/A -30.74% -22.23%

Does the media favor MESO or SYRE?

In the previous week, Mesoblast had 1 more articles in the media than Spyre Therapeutics. MarketBeat recorded 7 mentions for Mesoblast and 6 mentions for Spyre Therapeutics. Mesoblast's average media sentiment score of 0.44 beat Spyre Therapeutics' score of 0.43 indicating that Mesoblast is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mesoblast 1 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Spyre Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, MESO or IMVT?

Mesoblast has higher revenue and earnings than Immunovant. Mesoblast is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mesoblast $120.25M 15.16 -$57.50M -$0.28 N/A Immunovant N/A N/A -$505.61M -$2.82 N/A

Is MESO or IMVT more profitable?

Mesoblast's return on equity of 0.00% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Mesoblast N/A N/A N/A Immunovant N/A -69.59% -62.49%

Does the media prefer MESO or IMVT?

In the previous week, Immunovant had 4 more articles in the media than Mesoblast. MarketBeat recorded 11 mentions for Immunovant and 7 mentions for Mesoblast. Mesoblast's average media sentiment score of 0.44 beat Immunovant's score of 0.00 indicating that Mesoblast is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mesoblast 1 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immunovant 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral

Does the media prefer IONS or MESO?

In the previous week, Mesoblast had 2 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 7 mentions for Mesoblast and 5 mentions for Ionis Pharmaceuticals. Mesoblast's average media sentiment score of 0.44 beat Ionis Pharmaceuticals' score of 0.25 indicating that Mesoblast is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ionis Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mesoblast 1 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, MESO or ALKS?

Alkermes has higher revenue and earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mesoblast $120.25M 15.16 -$57.50M -$0.28 N/A Alkermes $1.48B 4.72 $241.66M $0.38 109.36

Is MESO or ALKS more profitable?

Alkermes has a net margin of 3.96% compared to Mesoblast's net margin of 0.00%. Alkermes' return on equity of 4.15% beat Mesoblast's return on equity. Company Net Margins Return on Equity Return on Assets Mesoblast N/A N/A N/A Alkermes 3.96% 4.15% 2.19%

Does the media refer more to MESO or ALKS?

In the previous week, Mesoblast had 3 more articles in the media than Alkermes. MarketBeat recorded 7 mentions for Mesoblast and 4 mentions for Alkermes. Alkermes' average media sentiment score of 0.82 beat Mesoblast's score of 0.44 indicating that Alkermes is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mesoblast 1 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alkermes 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, MESO or CGON?

Mesoblast has higher revenue and earnings than CG Oncology. Mesoblast is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mesoblast $120.25M 15.16 -$57.50M -$0.28 N/A CG Oncology $4.04M 1,486.74 -$160.99M -$2.69 N/A

Mesoblast (MESO) Competitors

$14.08 -0.24 (-1.68%)

Closing price 04:00 PM Eastern

Extended Trading

$14.08 -0.01 (-0.04%)

As of 07:30 PM Eastern

Compare

MESO vs. SYRE, IMVT, IONS, ALKS, and CGON

Should you buy Mesoblast stock or one of its competitors? Mesoblast's main competitors and comparable companies include Spyre Therapeutics (SYRE), Immunovant (IMVT), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), and CG Oncology (CGON). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Mesoblast compare to Spyre Therapeutics?

Mesoblast (NASDAQ:MESO) and Spyre Therapeutics (NASDAQ:SYRE) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

In the previous week, Mesoblast had 1 more articles in the media than Spyre Therapeutics. MarketBeat recorded 7 mentions for Mesoblast and 6 mentions for Spyre Therapeutics. Mesoblast's average media sentiment score of 0.44 beat Spyre Therapeutics' score of 0.43 indicating that Mesoblast is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mesoblast	1 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spyre Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Mesoblast has higher revenue and earnings than Spyre Therapeutics. Mesoblast is trading at a lower price-to-earnings ratio than Spyre Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	$120.25M	15.16	-$57.50M	-$0.28	N/A
Spyre Therapeutics	$890K	9,103.57	-$155.20M	-$1.95	N/A

Mesoblast's return on equity of 0.00% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mesoblast	N/A	N/A	N/A
Spyre Therapeutics	N/A	-30.74%	-22.23%

Mesoblast has a beta of 2.14, meaning that its stock price is 114% more volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.1, meaning that its stock price is 210% more volatile than the broader market.

1.4% of Mesoblast shares are owned by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are owned by institutional investors. 18.8% of Mesoblast shares are owned by company insiders. Comparatively, 15.7% of Spyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Mesoblast presently has a consensus price target of $39.00, indicating a potential upside of 177.78%. Spyre Therapeutics has a consensus price target of $109.71, indicating a potential upside of 19.08%. Given Mesoblast's higher probable upside, equities research analysts plainly believe Mesoblast is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Mesoblast beats Spyre Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Mesoblast compare to Immunovant?

Mesoblast (NASDAQ:MESO) and Immunovant (NASDAQ:IMVT) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.

1.4% of Mesoblast shares are held by institutional investors. Comparatively, 47.1% of Immunovant shares are held by institutional investors. 18.8% of Mesoblast shares are held by insiders. Comparatively, 1.9% of Immunovant shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Mesoblast has higher revenue and earnings than Immunovant. Mesoblast is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	$120.25M	15.16	-$57.50M	-$0.28	N/A
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A

Mesoblast's return on equity of 0.00% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mesoblast	N/A	N/A	N/A
Immunovant	N/A	-69.59%	-62.49%

Mesoblast has a beta of 2.14, meaning that its share price is 114% more volatile than the broader market. Comparatively, Immunovant has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market.

In the previous week, Immunovant had 4 more articles in the media than Mesoblast. MarketBeat recorded 11 mentions for Immunovant and 7 mentions for Mesoblast. Mesoblast's average media sentiment score of 0.44 beat Immunovant's score of 0.00 indicating that Mesoblast is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mesoblast	1 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immunovant	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

Mesoblast presently has a consensus price target of $39.00, suggesting a potential upside of 177.78%. Immunovant has a consensus price target of $44.00, suggesting a potential upside of 30.72%. Given Mesoblast's higher possible upside, equities research analysts clearly believe Mesoblast is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Immunovant	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

Summary

Mesoblast beats Immunovant on 9 of the 14 factors compared between the two stocks.

How does Mesoblast compare to Ionis Pharmaceuticals?

Ionis Pharmaceuticals (NASDAQ:IONS) and Mesoblast (NASDAQ:MESO) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends.

Mesoblast has a net margin of 0.00% compared to Ionis Pharmaceuticals' net margin of -64.76%. Mesoblast's return on equity of 0.00% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%
Mesoblast	N/A	N/A	N/A

In the previous week, Mesoblast had 2 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 7 mentions for Mesoblast and 5 mentions for Ionis Pharmaceuticals. Mesoblast's average media sentiment score of 0.44 beat Ionis Pharmaceuticals' score of 0.25 indicating that Mesoblast is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ionis Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mesoblast	1 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ionis Pharmaceuticals presently has a consensus target price of $89.20, indicating a potential upside of 105.52%. Mesoblast has a consensus target price of $39.00, indicating a potential upside of 177.78%. Given Mesoblast's higher possible upside, analysts plainly believe Mesoblast is more favorable than Ionis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ionis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.73
Mesoblast	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Ionis Pharmaceuticals has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market. Comparatively, Mesoblast has a beta of 2.14, suggesting that its stock price is 114% more volatile than the broader market.

93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.4% of Mesoblast shares are owned by institutional investors. 1.8% of Ionis Pharmaceuticals shares are owned by company insiders. Comparatively, 18.8% of Mesoblast shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Mesoblast has lower revenue, but higher earnings than Ionis Pharmaceuticals. Mesoblast is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ionis Pharmaceuticals	$944M	7.64	-$381.39M	-$3.46	N/A
Mesoblast	$120.25M	15.16	-$57.50M	-$0.28	N/A

Summary

Mesoblast beats Ionis Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Mesoblast compare to Alkermes?

Mesoblast (NASDAQ:MESO) and Alkermes (NASDAQ:ALKS) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation and earnings.

Mesoblast has a beta of 2.14, meaning that its share price is 114% more volatile than the broader market. Comparatively, Alkermes has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market.

1.4% of Mesoblast shares are held by institutional investors. Comparatively, 95.2% of Alkermes shares are held by institutional investors. 18.8% of Mesoblast shares are held by company insiders. Comparatively, 4.6% of Alkermes shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Alkermes has higher revenue and earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	$120.25M	15.16	-$57.50M	-$0.28	N/A
Alkermes	$1.48B	4.72	$241.66M	$0.38	109.36

Mesoblast currently has a consensus price target of $39.00, indicating a potential upside of 177.78%. Alkermes has a consensus price target of $54.47, indicating a potential upside of 31.07%. Given Mesoblast's higher probable upside, research analysts clearly believe Mesoblast is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Alkermes	1 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.74

Alkermes has a net margin of 3.96% compared to Mesoblast's net margin of 0.00%. Alkermes' return on equity of 4.15% beat Mesoblast's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mesoblast	N/A	N/A	N/A
Alkermes	3.96%	4.15%	2.19%

In the previous week, Mesoblast had 3 more articles in the media than Alkermes. MarketBeat recorded 7 mentions for Mesoblast and 4 mentions for Alkermes. Alkermes' average media sentiment score of 0.82 beat Mesoblast's score of 0.44 indicating that Alkermes is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mesoblast	1 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alkermes	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Alkermes beats Mesoblast on 12 of the 17 factors compared between the two stocks.

How does Mesoblast compare to CG Oncology?

Mesoblast (NASDAQ:MESO) and CG Oncology (NASDAQ:CGON) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.

1.4% of Mesoblast shares are owned by institutional investors. Comparatively, 26.6% of CG Oncology shares are owned by institutional investors. 18.8% of Mesoblast shares are owned by insiders. Comparatively, 4.8% of CG Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Mesoblast presently has a consensus price target of $39.00, suggesting a potential upside of 177.78%. CG Oncology has a consensus price target of $87.78, suggesting a potential upside of 29.54%. Given Mesoblast's higher probable upside, equities analysts plainly believe Mesoblast is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

In the previous week, Mesoblast had 7 more articles in the media than CG Oncology. MarketBeat recorded 7 mentions for Mesoblast and 0 mentions for CG Oncology. Mesoblast's average media sentiment score of 0.44 beat CG Oncology's score of 0.00 indicating that Mesoblast is being referred to more favorably in the media.

Company	Overall Sentiment
Mesoblast	Neutral
CG Oncology	Neutral

Mesoblast has a net margin of 0.00% compared to CG Oncology's net margin of -3,602.68%. Mesoblast's return on equity of 0.00% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mesoblast	N/A	N/A	N/A
CG Oncology	-3,602.68%	-25.20%	-23.98%

Mesoblast has higher revenue and earnings than CG Oncology. Mesoblast is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	$120.25M	15.16	-$57.50M	-$0.28	N/A
CG Oncology	$4.04M	1,486.74	-$160.99M	-$2.69	N/A

Mesoblast has a beta of 2.14, meaning that its share price is 114% more volatile than the broader market. Comparatively, CG Oncology has a beta of 0.28, meaning that its share price is 72% less volatile than the broader market.

Summary

Mesoblast beats CG Oncology on 11 of the 16 factors compared between the two stocks.

Get Mesoblast News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MESO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MESO vs. The Competition

Export

Metric	Mesoblast	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.86B	$3.87B	$7.14B	$13.10B
Dividend Yield	N/A	3.65%	2.54%	16.76%
P/E Ratio	-50.29	7.65	214.49	21.54
Price / Sales	15.21	1,292.25	607.75	91.81
Price / Cash	N/A	122.60	77.60	51.75
Price / Book	3.21	16.63	10.92	6.30
Net Income	-$57.50M	-$22.67M	$3.50B	$361.43M
7 Day Performance	-6.88%	-3.05%	-2.11%	-1.67%
1 Month Performance	-18.57%	-10.75%	-6.34%	-3.94%
1 Year Performance	-17.27%	21.11%	8.81%	2.77%

Mesoblast Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MESO Mesoblast	2.2758 of 5 stars	$14.08 -1.7%	$39.00 +177.0%	-12.0%	$1.86B	$120.25M	N/A	108	News Coverage
SYRE Spyre Therapeutics	2.0982 of 5 stars	$91.84 -0.2%	$109.69 +19.4%	+446.4%	$8.08B	$890K	N/A	112	Analyst Forecast
IMVT Immunovant	1.8727 of 5 stars	$37.46 +0.7%	$44.00 +17.5%	+105.9%	$7.74B	N/A	N/A	315
IONS Ionis Pharmaceuticals	3.1936 of 5 stars	$45.67 +1.7%	$90.50 +98.2%	-33.1%	$7.59B	$874.09M	N/A	1,402
ALKS Alkermes	3.08 of 5 stars	$44.30 +0.3%	$54.75 +23.6%	+32.3%	$7.43B	$1.48B	116.62	2,050

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MESO) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mesoblast (MESO) Competitors

MESO vs. SYRE, IMVT, IONS, ALKS, and CGON

How does Mesoblast compare to Spyre Therapeutics?

Summary

How does Mesoblast compare to Immunovant?

Summary

How does Mesoblast compare to Ionis Pharmaceuticals?

Summary

How does Mesoblast compare to Alkermes?

Summary

How does Mesoblast compare to CG Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MESO vs. The Competition

Mesoblast Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mesoblast (MESO) Competitors

MESO vs. SYRE, IMVT, IONS, ALKS, and CGON

How does Mesoblast compare to Spyre Therapeutics?

Does the media favor MESO or SYRE?

Which has preferable earnings and valuation, MESO or SYRE?

Is MESO or SYRE more profitable?

Which has more risk and volatility, MESO or SYRE?

Do insiders and institutionals believe in MESO or SYRE?

Do analysts rate MESO or SYRE?

Summary

How does Mesoblast compare to Immunovant?

Do insiders & institutionals hold more shares of MESO or IMVT?

Which has preferable valuation & earnings, MESO or IMVT?

Is MESO or IMVT more profitable?

Which has more volatility & risk, MESO or IMVT?

Does the media prefer MESO or IMVT?

Do analysts rate MESO or IMVT?

Summary

How does Mesoblast compare to Ionis Pharmaceuticals?

Is IONS or MESO more profitable?

Does the media prefer IONS or MESO?

Do analysts prefer IONS or MESO?

Which has more risk & volatility, IONS or MESO?

Do insiders and institutionals believe in IONS or MESO?

Which has preferable valuation & earnings, IONS or MESO?

Summary

How does Mesoblast compare to Alkermes?

Which has more volatility and risk, MESO or ALKS?

Do institutionals & insiders believe in MESO or ALKS?

Which has stronger earnings and valuation, MESO or ALKS?

Do analysts rate MESO or ALKS?

Is MESO or ALKS more profitable?

Does the media refer more to MESO or ALKS?

Summary

How does Mesoblast compare to CG Oncology?

Do insiders & institutionals have more ownership in MESO or CGON?

Do analysts rate MESO or CGON?

Does the media favor MESO or CGON?

Is MESO or CGON more profitable?

Which has preferable earnings & valuation, MESO or CGON?

Which has more volatility & risk, MESO or CGON?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MESO vs. The Competition

Mesoblast Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools